Covid-19: Only the second dose of the vaccine ensures significant protection among the elderly

Instituto Gulbenbenkian de Ciência, in partnership with Almeirim Municipality and the Group of Lezíria Health Centers, carried out a study in the elderly living in nursing homes, vaccinated with the Pfizer vaccine. The study measured antibodies against SARS-CoV- 2 before the vaccination, three to four weeks after the first dose and 3 weeks after the second dose. The results reveal that only 25% develop antibodies after the first dose, values ​​that reach 95% after the second dose. 5% of participants do not develop immunity after taking the vaccine. 

Check the latest news in the press about this study (in Portuguese):

in Público

in Observador

in RTP

in Expresso

in Jornal de Notícias

in Diário de Notícias

in Visão

in TVI


Updated on 29 april 2021

Cookies settings

Cookies Selection

The Calouste Gulbenkian Foundation uses cookies to improve your browsing experience, security, and its website performance. The Foundation may also use cookies to share information on social media and to display messages and advertisements personalised to your interests, both on our website and in others.